PFIZER INC

Pfizer’s pivot from COVID‑EUA sales to booming oncology drives future growth, with analysts pointing to a $30.17 target and a robust pipeline.

Pfizer’s new IBRANCE approval boosts its oncology prospects, while the CFO exit to Nike signals a strategic shift—what this means for investors and growth.

Pfizer’s new oncology wins: 7‑year CROWN data shows LORBRENA beats standard care, TALAPRO‑3 reduces prostate cancer progression, and a $10.5 b partnership with Innovent boosts China reach and future earnings.

Pfizer’s $10.5 B oncology deals with Innovent and I‑Mab plus Lorbrena’s seven‑year CROWN data promise growth but raise milestone, regulatory and pricing risks that investors must weigh.

Pfizer’s silent insiders, strong dividend yield, and FDA vaccine outlook paint a clear picture: a steady, income‑focused stock amid regulatory shifts and analyst optimism.

Pfizer’s bullish outlook: billionaire confidence, a 38% analyst upside, and $1.4B global partnerships signal strong future growth and a compelling entry point for investors.

Discover why Pfizer may be undervalued—deep dive into its strong cash flow, late‑stage oncology pipeline, AI partnerships, and upside potential.

Pfizer’s 25‑valent pneumococcal vaccine, showing 95% seroconversion in infants, now enters Phase III—offering broader pediatric protection and potential revenue boost.

Pfizer’s 2025 dividend jump, partnership with Mark Cuban to sell Eliquis, and focus on niche therapies show a resilient, investor‑friendly outlook.

Pfizer’s post‑COVID pivot: investing billions in oncology and obesity while juggling FDA scrutiny, dividend stability, and a $150B market opportunity.